Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Syngene International Limited (SYNGENE.NS)
Bengaluru, IN
Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The company's comprehensive service portfolio begins with discovery chemistry, encompassing medicinal and synthetic chemistry, library and peptide synthesis, biomolecule research, organic electronic materials, and specialized computational and analytical chemistry. In discovery biology, capabilities extend to recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK (Drug Metabolism and Pharmacokinetics), in vivo pharmacology, toxicology, and the development of biologicals. Syngene provides a full spectrum of toxicology services, from exploratory and in vitro studies to genetic, developmental, and reproductive toxicology, alongside acute, sub-chronic, and chronic toxicity assessments. Their development services include chemical, formulation, analytical, and clinical development, as well as commercial manufacturing. They also support crucial stages like lead generation, preclinical development, API (Active Pharmaceutical Ingredient) synthesis, and finished drug product development. For clinical trials, Syngene offers robust support, covering trial management, pharmacokinetic analysis/bioanalytical services, central laboratory operations, biometrics and clinical data management, regulatory affairs, medical monitoring, pharmacovigilance, and medical writing. Additionally, the company specializes in emerging drug modalities, such as peptides, oligonucleotide synthesis, antibody-drug conjugates (ADCs), PROTACs, and CAR T-cell therapies. Serving a diverse clientele that spans pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries, Syngene has established key collaborations with entities like Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc. Incorporated in 1993 and headquartered in Bengaluru, India, Syngene International Limited operates as a subsidiary of Biocon Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.04% | +5.18% | +18.00% | +6.98% | -28.07% | -26.65% | -23.67% | -31.75% | -18.05% | +151.18% | +207.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 2 | +1 |
| Sell | 1 | 0 |
| Strong Sell | 1 | -1 |
-
Revenue growth Biotechnology: +1.6%+2.6% ★ Q1'26: +1.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-36.2% Q1'26: -19.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+14.7% Q1'26: -19.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+14.1% ★ Q1'26: +20.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.1% ★ Q1'26: +16.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.1% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.47× ★ Q1'26: 0.35× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 5 EPS Ana. |
Mar 2027 8 Rev. Ana. 7 EPS Ana. |
Mar 2028 8 Rev. Ana. 6 EPS Ana. |
Mar 2029 5 Rev. Ana. 4 EPS Ana. |
Mar 2030 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
11.07B
est: 10.81B (+2.4%)
|
12.01B
est: 12.91B (-7.0%)
|
14.23B
est: 13.82B (+3.0%)
|
18.26B
est: 17.75B (+2.9%)
|
20.12B
est: 20.04B (+0.4%)
|
21.84B
est: 22.25B (-1.9%)
|
26.04B
est: 25.65B (+1.5%)
|
31.93B
est: 31.21B (+2.3%)
|
34.89B
est: 34.70B (+0.5%)
|
36.42B
est: 37.07B (-1.8%)
|
36.73B
35.80B – 37.76B
-0.9% YoY
|
39.73B
37.84B – 43.69B
+8.2% YoY
|
45.63B
40.52B – 50.57B
+14.9% YoY
|
51.23B
51.07B – 51.39B
+12.3% YoY
|
58.40B
53.60B – 64.49B
+14.0% YoY
|
| EBITDA |
3.97B
est: 3.12B (+27.2%)
|
3.83B
est: 4.28B (-10.6%)
|
3.98B
est: 5.69B (-30.2%)
|
5.35B
est: 7.97B (-32.8%)
|
5.91B
est: 7.03B (-15.9%)
|
6.44B
est: 8.89B (-27.6%)
|
7.26B
est: 10.62B (-31.7%)
|
9.59B
est: 13.61B (-29.5%)
|
10.30B
est: 9.78B (+5.4%)
|
9.91B
est: 21.73B (-54.4%)
|
10.35B
10.08B – 10.64B
-52.4% YoY
|
11.19B
10.66B – 12.31B
+8.2% YoY
|
12.85B
11.41B – 14.25B
+14.9% YoY
|
14.43B
14.39B – 14.47B
+12.3% YoY
|
16.45B
15.10B – 18.17B
+14.0% YoY
|
| EBIT |
3.01B
est: 1.93B (+56.3%)
|
2.70B
est: 3.59B (-24.7%)
|
2.69B
est: 2.87B (-6.3%)
|
3.75B
est: 3.47B (+8.0%)
|
3.84B
est: 4.24B (-9.5%)
|
3.86B
est: 4.28B (-9.9%)
|
4.34B
est: 5.12B (-15.3%)
|
6.17B
est: 6.56B (-5.9%)
|
6.47B
est: 5.93B (+9.0%)
|
6.14B
est: 6.35B (-3.3%)
|
6.28B
6.12B – 6.45B
-1.1% YoY
|
6.79B
6.47B – 7.47B
+8.2% YoY
|
7.80B
6.92B – 8.64B
+14.9% YoY
|
8.76B
8.73B – 8.78B
+12.3% YoY
|
9.98B
9.16B – 11.02B
+14.0% YoY
|
| Net Income |
2.41B
est: 2.23B (+7.9%)
|
2.87B
est: 2.87B (-0.1%)
|
3.05B
est: 3.04B (+0.3%)
|
3.32B
est: 3.95B (-16.0%)
|
4.12B
est: 3.76B (+9.7%)
|
4.05B
est: 4.60B (-11.9%)
|
3.96B
est: 5.49B (-27.9%)
|
4.64B
est: 7.03B (-34.0%)
|
5.10B
est: 4.92B (+3.6%)
|
4.96B
est: 5.07B (-2.2%)
|
3.17B
2.87B – 4.03B
-37.6% YoY
|
4.11B
3.12B – 4.61B
+29.8% YoY
|
5.62B
4.12B – 6.92B
+36.7% YoY
|
6.51B
6.30B – 8.86B
+15.8% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
2.68B
est: 3.10B (-13.6%)
|
3.27B
est: 4.21B (-22.2%)
|
4.07B
est: 4.72B (-13.6%)
|
5.03B
est: 7.76B (-35.1%)
|
6.01B
est: 8.04B (-25.3%)
|
6.79B
est: 9.31B (-27.1%)
|
7.50B
est: 11.12B (-32.5%)
|
8.94B
est: 14.26B (-37.3%)
|
9.40B
est: 9.15B (+2.8%)
|
10.33B
est: 22.75B (-54.6%)
|
9.68B
9.44B – 9.95B
-57.4% YoY
|
10.47B
9.98B – 11.52B
+8.2% YoY
|
12.03B
10.68B – 13.33B
+14.9% YoY
|
13.50B
13.46B – 13.55B
+12.3% YoY
|
15.39B
14.13B – 17.00B
+14.0% YoY
|
| EPS |
6.19
est: 5.55 (+11.5%)
|
7.35
est: 7.50 (-2.0%)
|
7.74
est: 7.34 (+5.4%)
|
8.38
est: 8.13 (+3.0%)
|
10.38
est: 8.81 (+17.9%)
|
10.18
est: 10.28 (-1.0%)
|
9.94
est: 10.08 (-1.4%)
|
11.59
est: 11.71 (-1.0%)
|
12.71
est: 12.27 (+3.6%)
|
12.35
est: 12.27 (+0.6%)
|
7.99
7.13 – 10.01
-34.9% YoY
|
10.29
7.75 – 11.46
+28.8% YoY
|
14.11
10.24 – 17.19
+37.2% YoY
|
18.89
15.67 – 22.02
+33.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 5/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.01% | 26.0K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 1.05M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 11.66M | 0.06% |
| 4 | Vanguard ESG International Stock ETF VSGX | 0.00% | 150.9K | 0.10% |
| 5 | Vanguard FTSE All-World ex-US ETF VEU | 0.00% | 2.04M | 0.04% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 12.76M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 638.5K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kiran Mazumdar-Shaw | Executive Chairperson | 10M | — |
| Peter James Jonathan Bains | Chief Executive Officer, MD & Director | 400.0K | male |
| Chethan Yogesh | Company Secretary & Compliance Officer | — | male |
| Deepak Jain | Chief Financial Officer | — | male |
| Gaurav Kushwaha | Chief Technology Officer | — | male |
| Jayashree Aiyar | Chief Scientific Officer | — | — |
| Krishnan | Head of Investor Relations | — | male |
| Mrinal Kammili | Head of Translational and Clinical Research | — | — |
| Nandini Agarwal | Investor Relations Officer | — | — |
| Pramuch Goel | Head of Corporate Affairs | — | male |
| Priyaranjan Pattanaik | Head of Biology | — | — |
| Rohtash Kumar | Head of CDMO, Small & Large Molecule | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SYNGENE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
